Neuraxis NRXS
NYSE NRXS
$6.15 -0.12 (-1.91%)
At close: Aug 21, 2026 · 4:00 PM EDT

Neuraxis (NRXS) Cash & Current Investments (2022 - 2026)

Neuraxis (NRXS) posted Cash & Current Investments of $7.1 million for Q1 2026, up 61.72% sequentially from $4.4 million in Q3 2025, and up 252.99% YoY from $2.0 million in Q1 2025.

Neuraxis (NRXS) Cash & Current Investments (2022 - 2026) Analysis & Trends

Neuraxis has reported Cash & Current Investments for 5 years, with the latest figure at $7.1 million in Q1 2026.

  • Quarterly Cash & Current Investments rose 252.99% year-over-year to $7.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.1 million (up 252.99% YoY) and the FY2023 annual result came in at $78560.0, down 69.03% from the prior year.
  • Cash & Current Investments climbed to $7.1 million in Q1 2026 per NRXS's latest filing, from $4.4 million in the prior quarter.
  • Over five years, Cash & Current Investments peaked at $7.1 million in Q1 2026 and troughed at $51440.0 in Q2 2023.
  • A 5-year average of $2.1 million and a median of $761249.0 in 2023 frame the typical range for Cash & Current Investments.
  • The sharpest annual moves came in 2023 and 2024: Cash & Current Investments sank 69.03% in 2023, then soared 3331.71% in 2024.
  • Over 5 years, Cash & Current Investments stood at $253699.0 in 2022, then tumbled by 69.03% to $78560.0 in 2023, then soared by 232.08% to $260885.0 in 2024, then jumped by 1577.79% to $4.4 million in 2025, then surged by 61.72% to $7.1 million in 2026.
  • According to Business Quant data, Cash & Current Investments over the past three periods registered $7.1 million, $4.4 million, and $6.0 million for Q1 2026, Q3 2025, and Q2 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Current Investments (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 7.85 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 7.99 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn 5.18 Bn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 5.14 Bn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 5.10 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 3.31 Bn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn 18.39 Bn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 1.16 Bn
9 Royalty Pharma 27.27 Bn 26.43 Bn - 836.99 Mn
10 Neuraxis 74.54 Mn 66.21 Mn - 8.32 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 8.32 Mn
Mar 31, 2026 7.08 Mn
Sep 30, 2025 4.38 Mn
Jun 30, 2025 5.99 Mn
Mar 31, 2025 2.01 Mn
Sep 30, 2024 260,885.00
Jun 30, 2024 1.77 Mn
Mar 31, 2024 81,752.00
Dec 31, 2023 78,560.00
Sep 30, 2023 761,249.00
Jun 30, 2023 51,440.00
Dec 31, 2022 253,699.00